biostudies-literatureZitomersky NNIDDK NIH HHS261-271https://www.ebi.ac.uk/biostudies/studies/S-EPMC10883602biostudies-literatureUnknown78(2)<h4>Background</h4>Infliximab (IFX) use is limited by loss of response often due to the development of anti-IFX antibodies and low drug levels.<h4>Methods</h4>We performed a single center prospective observational cohort study of pediatric and young adult subjects with inflammatory bowel disease (IBD) on IFX with over 3 years of follow-up. Infliximab levels (IFXL) and antibodies to infliximab (ATI) were measured throughout the study. Subjects were followed until IFX was discontinued.<h4>Results</h4>We enrolled 219 subjects with IBD (184: Crohn's disease; 33: Ulcerative colitis; and 2 Indeterminant colitis; 84 female, median age 14.4 years, 37% on concomitant immunomodulator). Nine hundred and nineteen serum samples (mean 4.2 ± 2.1 per patient) were tested for IFXL and ATI. During the studyJournal of pediatric gastroenterology and nutritionAnti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.PMC10883602K23 DK119584T32 DK007760P30 DK034854Chi LSilvester JAZitomersky NPapamichael KSnapper SBLiu EBray KRBousvaros ACheifetz ASfalseAnti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.<h4>Background</h4>Infliximab (IFX) use is limited by loss of response often due to the development of anti-IFX antibodies and low drug levels.<h4>Methods</h4>We performed a single center prospective observational cohort study of pediatric and young adult subjects with inflammatory bowel disease (IBD) on IFX with over 3 years of follow-up. Infliximab levels (IFXL) and antibodies to infliximab (ATI) were measured throughout the study. Subjects were followed until IFX was discontinued.<h4>Results</h4>We enrolled 219 subjects with IBD (184: Crohn's disease; 33: Ulcerative colitis; and 2 Indeterminant colitis; 84 female, median age 14.4 years, 37% on concomitant immunomodulator). Nine hundred and nineteen serum samples (mean 4.2 ± 2.1 per patient) were tested for IFXL and ATI. During the study2024-01-01T00:00:00Z2024 Feb2025-04-21T23:54:16.975Z2025-04-05T19:20:12.142ZS-EPMC108836023837455510.1002/jpn3.12074